-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Antibody-conjugated drugs (ADC) have both the cytotoxicity of small molecules and the targeting properties of monoclonal antibodies.
As one of the earliest enterprises in this field in China, Toyo Pharmaceuticals not only possesses the key technical capabilities of ADC research and development, but also has established a complete commercial production platform that conforms to GMP standards and integrates raw liquids and preparations.
The ADC process is complex and the production requirements are strict
ADC drugs are composed of antibodies, linkers, and cytotoxic drugs.
Precise
The choice of antibody depends on the target of the disease.
Coupling of small molecule drugs is also a key factor in determining ADC lethality.
Combining large-molecule drugs with small-molecule drugs may seem simple, but in reality it is extremely challenging.
All in all, safety, effectiveness, pharmacokinetics, quality control and production, as well as the challenges of clinical trials and regulatory supervision brought about by this, are all ADC R&D companies must face, and they need to have strong technology and experience accumulation.
Precise positioning and win-win cooperation to promote industrial development
After years of layout and intensive cultivation, Toyo Pharmaceutical has been in the first echelon in the domestic ADC field, whether it is the promotion of product pipelines or the establishment of commercial production platforms.
At present, the fastest ADC drug developed by Toyo Pharmaceutical is TAA013.
Breast cancer
On December 9, 2020, the results of the Phase I clinical study of TAA013 were released at the 2020 San Antonio Breast Cancer Conference (SABCS).
In terms of the commercial production of biopharmaceuticals, Toyo's production base has a designed production capacity of 16,000 liters, which can realize high-quality commercial production of drugs under research.
"ADC is a field with relatively high threshold and large investment.
Leave a message here
